Skip to main content
NASDAQ:BCDA

BioCardia Competitors

$3.44
+0.01 (+0.29 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.40
$3.54
50-Day Range
$3.26
$4.61
52-Week Range
$1.91
$8.60
Volume14,012 shs
Average Volume240,264 shs
Market Capitalization$57.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98

Competitors

BioCardia (NASDAQ:BCDA) Vs. ADMA, CASI, GNFT, XFOR, VYGR, and FENC

Should you be buying BCDA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to BioCardia, including ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), Genfit (GNFT), X4 Pharmaceuticals (XFOR), Voyager Therapeutics (VYGR), and Fennec Pharmaceuticals (FENC).

BioCardia (NASDAQ:BCDA) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for BioCardia and ADMA Biologics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCardia01202.67
ADMA Biologics00503.00

BioCardia currently has a consensus target price of $9.25, indicating a potential upside of 168.90%. ADMA Biologics has a consensus target price of $7.80, indicating a potential upside of 350.87%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than BioCardia.

Volatility and Risk

BioCardia has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Profitability

This table compares BioCardia and ADMA Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCardia-5,103.95%-496.87%-178.90%
ADMA Biologics-166.01%-98.83%-37.21%

Valuation and Earnings

This table compares BioCardia and ADMA Biologics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91

BioCardia has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 48.9% of ADMA Biologics shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Comparatively, 11.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats BioCardia on 9 of the 14 factors compared between the two stocks.

CASI Pharmaceuticals (NASDAQ:CASI) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Profitability

This table compares CASI Pharmaceuticals and BioCardia's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CASI Pharmaceuticals-402.87%-60.96%-42.48%
BioCardia-5,103.95%-496.87%-178.90%

Institutional & Insider Ownership

32.0% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.0% of BioCardia shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

CASI Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for CASI Pharmaceuticals and BioCardia, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CASI Pharmaceuticals00403.00
BioCardia01202.67

CASI Pharmaceuticals currently has a consensus price target of $4.20, suggesting a potential upside of 191.67%. BioCardia has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than BioCardia.

Earnings & Valuation

This table compares CASI Pharmaceuticals and BioCardia's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CASI Pharmaceuticals$4.13 million50.44$-46,030,000.00($0.42)-3.55
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32

BioCardia has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Summary

CASI Pharmaceuticals beats BioCardia on 9 of the 14 factors compared between the two stocks.

BioCardia (NASDAQ:BCDA) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for BioCardia and Genfit, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCardia01202.67
Genfit11402.50

BioCardia currently has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Genfit has a consensus price target of $51.00, suggesting a potential upside of 1,143.90%. Given Genfit's higher possible upside, analysts clearly believe Genfit is more favorable than BioCardia.

Risk & Volatility

BioCardia has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares BioCardia and Genfit's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32
Genfit$45.88 million4.09$-72,960,000.00($1.97)-2.08

BioCardia has higher earnings, but lower revenue than Genfit. Genfit is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCardia and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCardia-5,103.95%-496.87%-178.90%
GenfitN/AN/AN/A

BioCardia (NASDAQ:BCDA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares BioCardia and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCardia-5,103.95%-496.87%-178.90%
X4 PharmaceuticalsN/A-47.06%-35.89%

Analyst Ratings

This is a breakdown of recent recommendations for BioCardia and X4 Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCardia01202.67
X4 Pharmaceuticals00403.00

BioCardia currently has a consensus price target of $9.25, suggesting a potential upside of 168.90%. X4 Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 140.32%. Given BioCardia's higher possible upside, equities research analysts plainly believe BioCardia is more favorable than X4 Pharmaceuticals.

Insider & Institutional Ownership

9.0% of BioCardia shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 40.9% of BioCardia shares are owned by company insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares BioCardia and X4 Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.62

BioCardia has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCardia has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Summary

BioCardia beats X4 Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Voyager Therapeutics (NASDAQ:VYGR) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Insider & Institutional Ownership

78.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 9.0% of BioCardia shares are owned by institutional investors. 23.9% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 40.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Voyager Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Voyager Therapeutics and BioCardia, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Voyager Therapeutics09202.18
BioCardia01202.67

Voyager Therapeutics presently has a consensus price target of $10.55, suggesting a potential upside of 132.38%. BioCardia has a consensus price target of $9.25, suggesting a potential upside of 168.90%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Voyager Therapeutics.

Profitability

This table compares Voyager Therapeutics and BioCardia's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Voyager Therapeutics-60.61%-66.46%-17.92%
BioCardia-5,103.95%-496.87%-178.90%

Earnings and Valuation

This table compares Voyager Therapeutics and BioCardia's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$104.39 million1.64$-43,600,000.00($1.21)-3.75
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32

BioCardia has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Summary

BioCardia beats Voyager Therapeutics on 7 of the 13 factors compared between the two stocks.

Fennec Pharmaceuticals (NASDAQ:FENC) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares Fennec Pharmaceuticals and BioCardia's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-9.88
BioCardia$710,000.0081.36$-14,710,000.00($2.61)-1.32

Fennec Pharmaceuticals has higher earnings, but lower revenue than BioCardia. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fennec Pharmaceuticals and BioCardia's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/A-84.34%-75.51%
BioCardia-5,103.95%-496.87%-178.90%

Insider and Institutional Ownership

53.6% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 9.0% of BioCardia shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 40.9% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Fennec Pharmaceuticals and BioCardia, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00403.00
BioCardia01202.67

Fennec Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 129.43%. BioCardia has a consensus target price of $9.25, suggesting a potential upside of 168.90%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than Fennec Pharmaceuticals.

Volatility & Risk

Fennec Pharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.

Summary

Fennec Pharmaceuticals beats BioCardia on 8 of the 13 factors compared between the two stocks.


BioCardia Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.76+1.7%$209.81 million$29.35 million-2.05Earnings Announcement
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.49+3.4%$201.31 million$4.13 million-3.31Earnings Announcement
Analyst Report
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.10+0.2%$194.54 million$45.88 million-2.08
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.49+1.9%$177.18 millionN/A-2.34News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.54+0.4%$171.29 million$104.39 million-2.77
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.32+0.2%$164.34 millionN/A-7.71Earnings Announcement
Analyst Revision
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.84+1.0%$164.17 million$2.45 million-1.80Earnings Announcement
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.32+2.7%$153.07 millionN/A-4.42
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.72+0.4%$151.80 millionN/A-2.95
INmune Bio logo
INMB
INmune Bio
1.5$10.05+2.7%$150.08 millionN/A-10.36
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.60+4.1%$142.69 millionN/A-1.68Gap Down
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.30+7.0%$136.24 millionN/A0.00Earnings Announcement
Gap Down
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00+0.0%$132.41 million$2.33 million0.00Earnings Announcement
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.80+0.4%$131.76 million$32.12 million-75.38Analyst Downgrade
Axcella Health logo
AXLA
Axcella Health
1.6$3.37+0.3%$127.12 millionN/A-1.57
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.36+0.6%$122.03 millionN/A-3.20
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.23+1.8%$121.39 millionN/A-1.54
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.92+2.6%$121.25 million$20,000.000.00Upcoming Earnings
Gap Up
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.00+4.5%$112.51 millionN/A0.00Gap Up
PolarityTE logo
PTE
PolarityTE
1.5$0.93+1.8%$110.33 million$5.65 million-0.56Earnings Announcement
Gap Down
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.31+3.2%$104.54 millionN/A0.00
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.75+0.3%$102.93 million$23.05 million-1.67
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.00+0.5%$96.58 million$20.92 million-1.15Earnings Announcement
Dyadic International logo
DYAI
Dyadic International
1.3$3.50+6.6%$96.44 million$1.68 million-10.29Upcoming Earnings
Gap Down
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.01+0.0%$96.12 million$140,000.000.00Earnings Announcement
Upcoming Earnings
News Coverage
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.18+0.3%$95.80 million$3 million-1.99
ENTX
Entera Bio
1.2$3.03+3.3%$71.81 million$240,000.00-4.46Upcoming Earnings
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$3.88+3.1%$67.11 million$10,000.000.00Upcoming Earnings
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.14+3.5%$65.68 millionN/A-0.90
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.66+0.5%$58.60 million$420,000.00-1.38Earnings Announcement
Analyst Report
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.66+1.4%$55.00 million$10,000.000.00News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.81+2.5%$54.05 million$7.92 million-0.34Earnings Announcement
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.05+2.9%$52.54 million$1.45 million-0.37Gap Up
Organovo logo
ONVO
Organovo
0.7$7.25+1.4%$50.89 million$2.20 million0.00Upcoming Earnings
Microbot Medical logo
MBOT
Microbot Medical
1.3$6.73+0.1%$47.84 millionN/A0.00Upcoming Earnings
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$6.48+5.9%$44.73 millionN/A0.00News Coverage
Gap Up
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$1.68+4.8%$44.11 million$200,000.00-0.70Earnings Announcement
Gap Down
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.43+1.4%$42.04 million$192.41 million0.80
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$2.85+0.7%$32.36 millionN/A-0.94
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.43+4.5%$23.97 million$3.61 million-0.32Upcoming Earnings
News Coverage
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.